Talazoparib has FDA approval for HER2-negative breast cancer with germline BRCA1/2 mutations, and is currently in clinical trials for metastatic prostate cancer, alone and in combination with other agents29. This evidence concerns the gene BRCA1 and metastatic prostate carcinoma.